Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meridian Bioscience's wholly owned subsidiary, Meridian Life Science, has been awarded a five year $12.2 million contract by the National Institutes of Health to manufacture experimental vaccines.
Subscribe to our email newsletter
Meridian will manufacture up to 10 clinical experimental vaccines per year at its biopharmaceutical facility located in Memphis, Tennessee. Meridian will be working closely with the Laboratory of Infectious Diseases (LTD) of the National Institutes of Allergy and Infectious Diseases (NIAID), engaged in vaccine development and identification of new agents of viral diseases.
The contract requires production and safety testing of experimental non-influenza and influenza virus vaccines and other vaccine-related products for use in humans. Meridian will be manufacturing suspensions of viruses that have been shown by evaluation in vitro and in vivo to be promising candidates.
Richard Eberly, president, Meridian Life Science, said: “Through collaboration with the LID of the NIAID/NIH, we are hopeful that many of these experimental vaccines will ultimately be used for the prevention of viral diseases in humans.”